Placement of an electrode into the brain. The head is stabilised in a frame for stereotactic surgery. (Photo credit: Wikipedia)
Four of the six patients also experienced simultaneous changes in mood, anxiety, control over emotional responses, urges to binge and purge and other symptoms related to anorexia
In a world first, a team of researchers at the Krembil Neuroscience Centre and the University Health Network have shown that Deep Brain Stimulation (DBS) in patients with chronic, severe and treatment-resistant Anorexia Nervosa (anorexia) helps some patients achieve and maintain improvements in body weight, mood, and anxiety.
The results of this trial, entitled Deep Brain Stimulation of the Subcallosal Cingulate Area for Treatment-Refractory Anorexia Nervosa: A Phase I Pilot Trial, are published today in the medical journal The Lancet.
The study is a collaboration between lead author Dr. Nir Lipsman a neurosurgery resident at the University of Toronto and PhD student at the Krembil Neuroscience Centre; Dr. Andres Lozano, a neurosurgeon, at the Krembil Neuroscience Centre of Toronto Western Hospital and a professor and chairman of neurosurgery at the University of Toronto, whose research lab was instrumental in conducting the DBS research; and Dr. Blake Woodside, medical director of Canada’s largest eating disorders program at Toronto General Hospital and a professor of psychiatry at the University of Toronto.
The phase one safety trial investigated the procedure in six patients who would likely continue with a chronic illness and/or die a premature death because of the severity of their condition. The study’s participants had an average age of 38, and a mean duration of illness of 18 years. In addition to the anorexia, all patients, except one, also suffered from psychiatric conditions such as major depressive disorder and obsessive-compulsive disorder. At the time of the study, all patients currently, or had previously, suffered multiple medical complications related to their anorexia – altogether, the six patients had a history of close to 50 hospitalizations during their illnesses.
Study participants were treated with Deep Brain Stimulation (DBS), a neurosurgical procedure that moderates the activity of dysfunctional brain circuits. Neuroimaging has shown that there are both structural and functional differences between anorexia patients and healthy controls in brain circuits which regulate mood, anxiety, reward and body-perception.
Patients were awake when they underwent the procedure which implanted electrodes into a specific part of the brain involved with emotion, and found to be highly important in disorders such as depression. During the procedure, each electrode contact was stimulated to look for patient response of changes in mood, anxiety or adverse effects. Once implanted, the electrodes were connected to an implanted pulse generator below the right clavicle, much like a heart pacemaker.
Testing of patients was repeated at one, three, and six-month intervals after activation of the pulse generator device. After a nine-month period following surgery, the team observed that three of the six patients had achieved weight gain which was defined as a body-mass index (BMI) significantly greater than ever experienced by the patients. For these patients, this was the longest period of sustained weight gain since the onset of their illness.
Furthermore, four of the six patients also experienced simultaneous changes in mood, anxiety, control over emotional responses, urges to binge and purge and other symptoms related to anorexia, such as obsessions and compulsions. As a result of these changes, two of these patients completed an inpatient eating disorders program for the first time in the course of their illness.
“We are truly ushering in a new of era of understanding of the brain and the role it can play in certain neurological disorders,” says Dr. Lozano. “By pinpointing and correcting the precise circuits in the brain associated with the symptoms of some of these conditions, we are finding additional options to treat these illnesses.”
The Latest Bing News on:
Deep brain stimulation
- Deep Brain Stimulation Shown to Improve Anxiety, Depression in PDon August 6, 2022 at 8:40 am
Patients with Parkinson disease (PD) exhibited significant improvement in measurement scales for depression and anxiety when treated with subthalamic nucleus deep brain stimulation.
- Chennai Hospital performs deep brain stimulation surgery on Sudanese Manon August 3, 2022 at 11:40 pm
City-based MGM Healthcare on Monday said it has 'successfully' performed a deep brain stimulation (DBS) surgery on a 34-year-old man from Sudan who was suffering from Wilson's disease for ...
- Improving human brain cognition with noninvasive, personalized treatments wins prizeon August 3, 2022 at 5:00 pm
For his work in utilizing new technologies to personalize noninvasive treatments for various cognitive brain disorders, such as aging-related memory decline, Robert Reinhart is the 2022 grand prize ...
- 34-year-old man undergoes deep brain stimulation surgeryon August 1, 2022 at 10:41 am
Doctors of MGM Healthcare performed a deep brain stimulation (DBS) surgery on a 34-year-old man from Sudan who was suffering from Wilson’s disease for nine years. According to a press release, the ...
- Deep Brain Stimulation Market Research | 2022 Is Booming Worldwide Business Forecast By 2031on August 1, 2022 at 12:00 am
Deep Brain Stimulation Market Key Players Industry Overview Supply And Consumption Demand And Forecast To 2031 NEW YORK CITY, NEW ...
- Hyper Direct Brain-Muscle Pathway Inhibits Initiated Movements in Humanson July 27, 2022 at 5:00 am
Scientists identify a causal role for the subthalamic nucleus in the blocking of muscle movements already initiated.
- Researchers confirm brain region's role in mind-body communicationon July 26, 2022 at 10:35 am
University of Iowa researchers have confirmed in a new study that a specific region in the brain is critical to governing the mind's communication with the body's motor control system. The findings ...
- Deep-brain stimulation can help reduce alcohol cravings and consumption, study findson July 22, 2022 at 11:14 am
In a pilot study, Toronto researchers found they were able to safely reduce alcohol cravings and consumption in individuals with severe alcohol use disorder by treating them with deep brain ...
- Deep Brain Stimulation Devices Market Overview, Industry Statistics, Trends, Size, Growth, Share, Demand and Forecast to 2031on July 20, 2022 at 11:00 pm
The array of approved deep brain stimulation (DBS) devices worldwide has expanded strikingly to treat hard-to-manage movement disorders due to malfunctioning of pathological circuits in the brain.
- Global Deep Brain Stimulation Market Size, Market Share, Status, Business Analysis, SWOT Analysis And Forecast To 2022-2028on July 11, 2022 at 11:41 pm
The Global Deep Brain Stimulation Market is valued at USD 1068.9 Million in 2021 and is expected to reach USD 1892.2 Million by 2028 with a CAGR of 8.50% over the forecast period.
The Latest Google Headlines on:
Deep brain stimulation
[/vc_column_text]
The Latest Bing News on:
Anorexia Nervosa
- Pipeline Moves: Phase II gout trial termination slashes advancement prospectson August 3, 2022 at 2:30 am
This week on Pipeline Moves, we look into the termination of a Phase II trial in gouty arthritis (gout). We also feature the positive topline safety and tolerability data from a Phase Ib trial in ...
- Children can develop eating disorders well before they become teenagers, research showson August 2, 2022 at 9:26 pm
Eating disorders most often are diagnosed in the teen and young adult years, but research on younger populations has shown that they can start much earlier in childhood. A study, published Monday, ...
- Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compoundon July 28, 2022 at 1:19 pm
Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia ...
- COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosaon July 28, 2022 at 7:47 am
Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved ...
- COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosaon July 28, 2022 at 4:08 am
The phase II clinical trial will compare the effects of 25 mg and 1 mg of investigational COMP360 psilocybin when administered with psychological support, in 60 participants with anorexia nervosa ...
- COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosaon July 28, 2022 at 3:06 am
Anorexia carries the highest mortality rate (5.86)1 of all psychiatric disorders because of medical complications and suicide;2 approximately 20-40% of deaths in anorexia nervosa are thought to ...
- COMPASS Pathways Launches Phase II Clinical Trial Of Psilocybin Therapy In Anorexia Nervosaon July 28, 2022 at 2:05 am
Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved ...